



Infectious
Diseases Labs

A*STAR IDL

Dr. Marc P. Windisch



Senior Director and Project Team Leader
Assembly Biosciences
PhD in Molecular Virology
Heidelberg University Hospital



Friday 11 September 2026

11:00 AM to 12:00 PM (SGT)

Venue: Matrix, Level 5, Cistron A & B

- From Bench to Bedside – ABI-6250, a First-in-Class Oral Drug Candidate for Chronic Hepatitis D

Chronic hepatitis D virus (cHDV) infection is the most severe form of viral hepatitis, driving accelerated progression to cirrhosis and hepatocellular carcinoma, with treatment options remaining limited. Bulevirtide (BLV), an injectable peptide that blocks HDV entry by binding the sodium taurocholate co-transporting polypeptide (NTCP) receptor — a bile acid transporter — is approved in Europe and the USA for cHDV treatment.

This talk outlines the development of ABI-6250, a first-in-class, orally bioavailable small-molecule NTCP-targeting HDV entry inhibitor, covering: (i) preclinical profiling of ABI-6250 as a potential oral alternative to injectable NTCP-targeted therapy; (ii) Phase 1a clinical trial data; and (iii) an outlook on extending NTCP-targeted inhibition to cholestatic liver diseases beyond cHDV.

Dr. Marc P. Windisch is a virologist and antiviral drug discovery leader with nearly 20 years of experience spanning hit discovery through Phase 1 clinical development. He serves as Senior Director and Project Team Leader at Assembly Biosciences, where he leads cross-functional programs developing novel therapies for chronic hepatitis D, other viral diseases, and cholestatic liver diseases.

Previously, Dr. Windisch spent more than a decade at Institut Pasteur Korea, where he served as Executive Director and Group Leader of the Applied Molecular Virology Laboratory. His teams advanced antiviral discovery programs targeting HCV, HBV, HDV, Ebola, Zika, coronaviruses, etc.

Dr. Windisch earned his PhD in Molecular Virology from Heidelberg University Hospital under Professor Ralf Bartenschlager and has held a professorship in South Korea. He has authored 65 peer-reviewed publications and is an inventor on 11 provisional patent applications and two international patents.

Hosted by: Dr Stefan Oehlers

Seminar is open to all. No registration required.

Questions? Contact us at seminars@a-star.edu.sg

Brought to you by A*STAR IDL